Novozymes A/S (OTCMKTS:NVZMY)’s share price crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $77.53 and traded as low as $72.40. Novozymes A/S shares last traded at $73.17, with a volume of 7,399 shares trading hands.
Several equities research analysts have recently weighed in on the company. Berenberg Bank raised Novozymes A/S from a “hold” rating to a “buy” rating in a research note on Monday, August 23rd. Credit Suisse Group reaffirmed an “underperform” rating on shares of Novozymes A/S in a research note on Monday, August 16th. Zacks Investment Research raised Novozymes A/S from a “sell” rating to a “hold” rating in a research note on Thursday, August 19th. UBS Group reaffirmed a “sell” rating on shares of Novozymes A/S in a research note on Friday, August 13th. Finally, Barclays reissued an “overweight” rating on shares of Novozymes A/S in a research note on Thursday, September 2nd. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $81.00.
The company has a quick ratio of 0.89, a current ratio of 1.44 and a debt-to-equity ratio of 0.35. The stock has a 50 day simple moving average of $77.53 and a 200 day simple moving average of $72.95. The stock has a market cap of $16.70 billion, a price-to-earnings ratio of 42.05, a PEG ratio of 8.56 and a beta of 0.43.
Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark.
Featured Story: Basic Economics creates winners and losers
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.